

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
14 August 2025 (14.08.2025)



(10) International Publication Number
WO 2025/171378 A1

(51) International Patent Classification:
C07K 16/28 (2006.01) A61K 39/00 (2006.01)

LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:
PCT/US2025/015227

Published:

(22) International Filing Date:
10 February 2025 (10.02.2025)

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/552,089 09 February 2024 (09.02.2024) US

(71) Applicant: **REZOLUTE, INC.** [US/US]; 201 Redwood Shores Pkwy, Suite 315, Redwood City, California 94065 (US).

(72) Inventors: **HOOD, Davelyn Eaves**; 201 Redwood Shores Pkwy, Suite 315, Redwood City, California 94065 (US). **AKANA, Cody Keoki**; 201 Redwood Shores Pkwy, Suite 315, Redwood City, California 94065 (US). **BREIT, Jeffrey Francis**; 201 Redwood Shores Pkwy, Suite 315, Redwood City, California 94065 (US). **ROBERTS, Brian Kenneth**; 201 Redwood Shores Pkwy, Suite 315, Redwood City, California 94065 (US). **SAHA, Gopal Chandra**; 201 Redwood Shores Pkwy, Suite 315, Redwood City, California 94065 (US).

(74) Agent: **NEVILLE, Katherine L.**; MARSHALL, GERSTEIN & BORUN LLP, 233 S. Wacker Drive, 6300 Willis Tower, Chicago, Illinois 60606-6357 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,

(54) Title: INSULIN RECEPTOR MODULATION FOR TUMOR ASSOCIATED HYPERINSULINISM

(57) Abstract: The present disclosure describes the use of an anti-insulin receptor antibody to treat neoplasms and/or tumor-associated hyperinsulinism and resulting hypoglycemia caused by benign or malignant neoplastic production of insulin and/or other effector substances (e.g., IGF-2 or its variants) that interact with the INSR and thus result in insulin-like action.

WO 2025/171378 A1